Eli Lilly launched TuneLab, a platform granting small biotech firms access to Lilly’s extensive AI models trained on decades of internal data, focusing on small-molecule drug properties and antibody development. This collaborative initiative requires data sharing for mutual model improvement via federated learning, preserving proprietary information. It aims to democratize cutting-edge AI capabilities in drug discovery, helping smaller companies accelerate candidate evaluation. The platform is part of Lilly's broader Catalyze360 effort to foster external innovation through strategic technology sharing.